ArticleAIDS research and therapy2012
Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.
Article in AIDS research and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Antiviral Effects and Mechanisms of Active Ingredients in Tea.Molecules (Basel, Switzerland) · 2024Review
- Epigallocatechin gallate (EGCG) combined with zinc sulfate inhibits Peste des petits ruminants virus entry and replication.Saudi journal of biological sciences · 2021Article
- Food Containing Bioactive Flavonoids and Other Phenolic or Sulfur Phytochemicals With Antiviral Effect: Can We Design a Promising Diet Against COVID-19?Frontiers in nutrition · 2021Review
- Research Progress of the Antiviral Bioactivities of Natural Flavonoids.Natural products and bioprospecting · 2020Review
- A Comprehensive Insight on the Health Benefits and Phytoconstituents ofAntioxidants (Basel, Switzerland) · 2019Review
- Impact of semen-derived amyloid (SEVI) on sperm viability and motility: its implication in male reproductive fitness.European biophysics journal : EBJ · 2019Article
- Antiviral Mechanism of Action of Epigallocatechin-3-Molecules (Basel, Switzerland) · 2018Review
- Structure, function and antagonism of semen amyloids.Chemical communications (Cambridge, England) · 2018Review
- Epigallocatechin-3-gallate local pre-exposure application prevents SHIV rectal infection of macaques.Mucosal immunology · 2018Article
- A Review of the Antiviral Role of Green Tea Catechins.Molecules (Basel, Switzerland) · 2017Review
- Article
- Epigallocatechin Gallate Inhibits Macaque SEVI-Mediated Enhancement of SIV or SHIV Infection.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Article
- Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide.BMC infectious diseases · 2016Article
- Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.Journal of natural medicines · 2016Article
- Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils.Biology open · 2015Article
- Morphology-Dependent HIV-Enhancing Effect of Semen-Derived Enhancer of Viral Infection.Biophysical journal · 2015Article
- Article
- Interaction of fibronectin with semen amyloids synergistically enhances HIV infection.The Journal of infectious diseases · 2014Article
- Liquefaction of semen generates and later degrades a conserved semenogelin peptide that enhances HIV infection.Journal of virology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, it has been shown that human ejaculate enhances human immunodeficiency virus 1 (HIV-1) infectivity. Enhancement of infectivity is conceived to be mediated by amyloid filaments from peptides that are proteolytically released from prostatic acid phosphatase (PAP), termed Semen-derived Enhancer of Virus Infection (SEVI). The aim of this study was to test the range of HIV-1 infectivity enhancing properties of a large number of individual semen samples (n = 47) in a TZM-bl reporter cell HIV infection system. We find that semen overall increased infectivity to 156% of the control experiment without semen, albeit with great inter- and intraindividual variability (range -53%-363%). Using transmission electron microscopy, we provide evidence for SEVI fibrils in fresh human semen for the first time. Moreover, we confirm that the infectivity enhancing property can be inhibited by the major green tea ingredient epigallocatechin-3-gallate (EGCG) at non-toxic concentrations. The median inhibition of infection by treatment with 0.4 mM EGCG was 70.6% (p < 0.0001) in our cohort. Yet, there were substantial variations of inhibition and in a minority of samples, infectivity enhancement was not inhibited by EGCG treatment at all. Thus, topical application of EGCG may be a feasible additional measure to prevent the sexual transmission of HIV. However, the reasons for the variability in the efficacy of the abrogation of semen-mediated enhancement of HIV-1 infectivity and EGCG efficacy have to be elucidated before therapeutic trials can be conducted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.